From Seekingalpha · Edmund Ingham · · 30s
JNJ Q3 Earnings Drop Amid Talc Litigation
Johnson & Johnson's Q3 earnings fell as talc litigation costs and medtech slowdown hit.
In brief
Johnson & Johnson's Q3 earnings fell as talc litigation costs and medtech slowdown hit. Johnson & Johnson reported 6% revenue growth but 7.5% lower earnings due to talc litigation costs and medtech underperformance. Originally reported by Seekingalpha.
Q3 Results
Johnson & Johnson reported 6% revenue growth to $25.4bn but 7.5% lower earnings year-on-year.
Talc Litigation Plan
Jnj set aside $5.5bn for talc litigation aiming for 95% plaintiff participation.
MedTech Underperformance
Medtech division slowed growth as orthopedics unit spin-off planned.
The headline
Johnson & Johnson reported 6% revenue growth but 7.5% lower earnings due to talc litigation costs and medtech underperformance.
